Growing pain market to bode well for IX Biopharma

It has five drugs under development.

Combining with the sublingual delivery method to improve drug absorption and bioavailability to achieve a lower dosage, iX Biopharma’s products could potentially be key drugs in their respective market segments, said DBS Vickers Securities.

iX Biopharma, a speciality pharmaceutical company with expertise in formulation and drug delivery, currently has five drugs under development – three are for pain management: WafermineTM, BnoXTM and WafernylTM; WafeRestTM for jetlag and improved sleep quality; and PheoniXTM for the treatment of male erectile dysfunction.

According to DBS Vickers Securities, the global pain management is growing, especially with the ageing population.

"We expect iX Biopharma to capture a significant market share once WafermineTM and BnoXTM are ready for commercialisation and exportation, likely in late 2018/ early 2019," it said.

The research firm added that to fund further R&D and clinical operations and to accelerate profitability, iX Biopharma could explore out-licensing opportunities likely in 3Q17.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia